Benefits, harms, and cost-effectiveness of potential age extensions to the national bowel cancer screening program in Australia

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 12, 2018, Pages 1450-1461

  Lew, Jie Bin ^a,b   St John, D James B ^c,d   Macrae, Finlay A ^d   Emery, Jon D ^d,e   Ee, Hooi C ^f   Jenkins, Mark A ^g   He, Emily ^a,b   Grogan, Paul ^h   Caruana, Michael ^a,b   Greuter, Marjolein J E ⁱ   Coupe, Veerle M H ⁱ   Canfell, Karen ^a,b,j  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANCER COUNCIL AUSTRALIA   (Australia)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CANCER INCIDENCE; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VERY ELDERLY; AGE; AUSTRALIA; COLON TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; PROCEDURES;

AGE FACTORS; AGED; AGED, 80 AND OVER; AUSTRALIA; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED;

EID: 85057748227     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-18-0128     Document Type: Article

References (36)

1. Australian Institute of Health and Welfare. National Bowel Cancer Screening Program: monitoring report 2013–14. Cancer series No. 94. Cat. no. CAN 94. Canberra: AIHW; 2015.
2. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van BM, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149.
3. Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA 2016;315:2595–609.
4. Bolin TD, Korman MG, Nicholson F, Pezzullo L, Engelman J, Collings K, et al. Cost-effectiveness of screening for bowel cancer. Med J Aust 2016; 204:11–2.
5. Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia; 2017.
6. Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, et al. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Int J Cancer 2018;143:269–82.
7. Lew JB, St John DJ, Xu XM, Greuter MJE, Caruana M, Cenin DR, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health 2017;2:e331–40.
8. Greuter MJ, Xu XM, Lew JB, Dekker E, Kuipers EJ, Canfell K, et al. Modeling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA). Risk Anal 2014;34:889–910.
9. Australian Institute of Health and Welfare (AIHW). GRIM (General Record of Incidence of Mortality) books 2013: All causes combined. Canberra: AIHW; 2015.
10. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books: Bowel cancer. Canberra: AIHW; 2014.
11. Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical Practice Guidelines for Surveillance Colonoscopy – in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Cancer Council Australia, Sydney. 2011.
12. Barclay K. Cancer Council Australia Surveillance Colonoscopy Guidelines Working Party. Algorithm for Colonoscopic Surveillance Intervals – Adenomas. 2013. http://www.gastroservices.com.au/pdf/algorithmfor-colonoscopic-surveillance-intervals-adenomas.pdf (accessed 28-12-2016).
13. Australian Institute of Health and Welfare (AIHW). Cervical screening in Australia 2014–2015. Cancer series no. 105. Cat. no. CAN 104. Canberra: AIHW; 2017.
14. Australian Institute of Health and Welfare (AIHW). BreastScreen Australia monitoring report 2013–2014.Cancer series no. 100. Cat. no. CAN 99. Canberra: AIHW; 2017.
15. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program: monitoring report 2018. Cat. no. CAN 112. Canberra: AIHW; 2018.
16. Cenin DR, St John DJ, Ledger MJ, Slevin T, Lansdorp-Vogelaar I. Optimising the expansion of the National Bowel Cancer Screening Program. Med J Aust 2014;201:456–61.
17. Australian Government Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines. 2016. https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf (accessed 18-4-2018).
18. Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health 2017;2:e96–107.
19. Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol 2015;30:6–13.
20. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books: Colorectal cancer (also called bowel cancer). Canberra: AIHW; 2017.
21. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc 2011;74:885–96.
22. Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Sydney: Cancer Council Australia; 2016.
23. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst 2017;109. doi: 10.1093/jnci/djw322.
24. Australian Government Department of Health. Medicare Benefits Schedule Book (Operating from 01 January 2014). Canberra: Australia Government Department of Health; 2013.
25. Independent Hospital Pricing Authority. National Hospital Cost Data Collection Australia Public Hospitals Cost Report 2011–2012, Round 16. New South Wales: IHPA; 2014.
26. Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJ. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust 2011;194:180–5.
27. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343–50.
28. Jentschura D, Raute M, Winter J, Henkel T, Kraus M, Manegold BC. Complications in endoscopy of the lower gastrointestinal tract. Therapy and prognosis. Surg Endosc 1994;8:672–6.
29. Morris M, Iacopetta B, Platell C. Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals. Med J Aust 2007;186:296–300.
30. Parente F, Vailati C, Boemo C, Bonoldi E, Ardizzoia A, Ilardo A, et al. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Dig Liver Dis 2015;47:68–72.
31. Gill MD, Bramble MG, Hull MA, Mills SJ, Morris E, Bradburn DM, et al. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers. Br J Cancer 2014; 111:2076–81.
32. Pande R, Froggatt P, Baragwanath P, Harmston C. Survival outcome of patients with screening versus symptomatically detected colorectal cancers. Colorectal Dis 2013;15:74–9.
33. Australian Bureau of Statistics. Consumer Price Index: March Quarter 2013. Canberra, Australia: Australian Bureau of Statistics; 2013.
34. Australian Bureau of Statistics. Consumer Price Index: March Quarter 2015. Canberra, Australia: Australian Bureau of Statistics; 2015.
35. Ananda S, Kosmider S, Tran B, Field K, Jones I, Skinner I, et al. The rapidly escalating cost of treating colorectal cancer in Australia. Asia-Pac J Clin Oncol 2016;12:33–40.
36. St John J, Grogan P. Compelling new data on the effectiveness of Australia's National Bowel Cancer Screening Program: A model for best practice? Asia-Pac J Clin Oncol 2016;12:7–9.